Results 51 to 60 of about 6,623 (164)

AN INTERESTING CASE OF FAMILIAL HOMOZYGOUS HYPERCHOLESTEROLEMIA , SFH RIYADH KSA.

, 2017
Familial hypercholesterolemia is an inherited condition that cause high level of LDL and cholesterol levels beginning birth . Familial hypercholesterolemia is run in families in an autosomal manner .
Amjaad AlMarjan, Amjaad Al Marjan, Fawwaz Al Mutairi., Fawwaz AlMutairi.   +3 more
core   +1 more source

Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia [PDF]

, 1999
Background The aortic valve dysfunction of patients with homozygous familial hypercholesterolemia (FH) suggests that hypercholesterolemia affects not only coronary arteries, but also the aortic valve.
Yutani, Chikao, Miyatake, Kunio, Tsushima, Motoo, Yamamura, Taku, Beppu, Shintarou, Yamamoto, Akira, Kawaguchi, Akito   +6 more
core   +1 more source

APOE genotype and the effect of statins on lipid outcomes: A meta‐analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1268-1286, May 2026.
Aim APOE genotype may affect statin therapy response. We conducted a meta‐analysis to update and quantify this association across various outcomes. Methods We searched seven databases (MEDLINE, Scopus, Web of Science, the Cochrane Library, APA PsycINFO, CINAHL Plus and ClinicalTrials.gov) on 9 May 2024.
Innocent G. Asiimwe, Tsegay Gebru, Andrea L. Jorgensen, Munir Pirmohamed, on behalf of the Multimorbidity Mechanism and Therapeutics Research Collaborative   +4 more
wiley   +1 more source

Mecanismos moleculares que relacionam a hipercolesterolemia familiar à doença de Alzheimer [PDF]

, 2015
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas, Programa de Pós-Graduação em Bioquímica, Florianópolis, 2015.A hipercolesterolemia familiar é uma doença do metabolismo das lipoproteínas causada por anormalidades ...
Oliveira, Jade de
core  

Lomitapide: a novel drug for homozygous familial hypercholesterolemia [PDF]

, 2014
Lomitapide (Juxtapid® and Lojuxta®; Aegerion Pharmaceuticals, Inc., MA, USA), an orally administered inhibitor of the microsomal triglyceride transfer protein, inhibits the synthesis and secretion of ApoB-containing lipoproteins and, thus, reduces plasma
AVERNA, Maurizio, CEFALU', Angelo Baldassare, Panno, MD   +2 more
core   +1 more source

Engineering exosomal cargo loading via endogenous molecular pathways: Strategies to enhance therapeutic potential

Interdisciplinary Medicine, Volume 4, Issue 3, May 2026.
This review illustrates how scientists engineer exosomes by hijacking the cell's own cargo‐sorting machinery. These strategies efficiently load therapeutic molecules into natural vesicles, creating powerful next‐generation drug delivery systems (Created with BioGDP.com).
Huanrong Zhu, Chenning Zhang, Shihan Ma, Zhanxue Xu, Cailing Liang, Fang Cheng, Hongbo Chen   +6 more
wiley   +1 more source

GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy

Nature Communications, 2023
Lipid nanoparticles have demonstrated utility in hepatic delivery of a range of therapeutic modalities and typically deliver their cargo via low-density lipoprotein receptor-mediated endocytosis.
Lisa N. Kasiewicz, Souvik Biswas, Aaron Beach, Huilan Ren, Chaitali Dutta, Anne Marie Mazzola, Ellen Rohde, Alexandra Chadwick, Christopher Cheng, Sara P. Garcia, Sowmya Iyer, Yuri Matsumoto, Amit V. Khera, Kiran Musunuru, Sekar Kathiresan, Padma Malyala, Kallanthottathil G. Rajeev, Andrew M. Bellinger   +17 more
doaj   +1 more source

Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship

, 2016
Background-Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremely high risk of premature atherosclerotic cardiovascular disease.
Mosquera, D., Sánchez Hernández, Rosa María, Almagro Múgica, Fátima, Mosquera, Daniel, Brito Casillas, Yeray, Blanco Vaca, Francisco, Stef, M., Saenz-Aranzubia, Pedro, Pocovi, M., Mosquera Lozano, Daniel, Civeira, Fernando, Plana Gil, Nuria, Brito-Casillas, Y., Civeira Murillo, Fernando, Fuentes, Francisco J., Sánchez-Hernández, R. M., Ascaso Gimilio, Juan Francisco, Soler i Ferrer, Cristina, Real, J. T., Novoa, Francisco J., Almagro, F., Stef, Marianne A., Perez-Calahorra, Sofia, Civeira, F., Novoa Mogollón, Francisco, Perez-Calahorra, S., Blanco-Vaca, F., Fuentes Jiménez, Francisco José, Real, Jose T., Ascaso, J. F., Sáenz-Aranzubía, P., Plana, Nuria, Brito-Casillas, Yeray, Pérez Calahorra, Sofía, Soler, Cristina, Sanchez-Hernandez, Rosa M., Blanco-Vaca, Francisco, Plana, N., Fuentes, F. J., Sáenz Aranzubía, Pedro Enrique, Pocovi Mieras, Miguel, Real Collado, José Tomás, Soler, C., Stef, Marianne, Pocovi, Miguel, Almagro, Fatima, Ascaso, Juan F., Novoa, F. J.   +47 more
core   +1 more source

New algorithms for treating homozygous familial hypercholesterolemia

, 2022
We reviewed current and future therapeutic options for patients with homozygous familial hypercholesterolemia (HoFH) and place this evidence in context of an adaptable treatment algorithm. RECENT FINDINGS: Lowering LDL-C levels to normal in patients with
Tromp, Tycho R., Cuchel, Marina
core   +1 more source

Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians

Pregnancy, Volume 2, Issue 3, May 2026.
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld, Nicole Kasatkin, Bi Liu Yu, Milen Velinov, Justin S. Brandt, Elena Ashkinadze   +5 more
wiley   +1 more source